Vor Bio (VOR) announced that the primary endpoint was achieved in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults ...
Results from the pivotal LIBERTY-AFRS-AIMS phase 3 study evaluating the investigational use of Dupixent in adults and children aged 6 years and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback